---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-173847"
form_type: "8-K"
ticker: "INO"
cik: "0001055726"
company_name: "INOVIO PHARMACEUTICALS, INC."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T17:34:41.968391+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Inovio settles derivative litigation; court preliminarily approves governance reforms and $1.175M fee award

## Summary
- Court preliminarily approved settlement of derivative lawsuit alleging misleading statements on COVID-19 vaccine INO-4800.
- Settlement includes corporate governance reforms and $1,175,000 payment for plaintiffs' attorneys' fees, subject to court approval.
- Final settlement hearing scheduled for October 11, 2023.
- Defendants deny wrongdoing; settlement is without admission of liability.
- Governance reforms address internal controls and oversight deficiencies alleged in complaints.

## SEC filing metadata
- accession: 0001193125-23-173847
- form_type: 8-K
- ticker: INO
- cik: 0001055726
- company_name: INOVIO PHARMACEUTICALS, INC.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1055726/000119312523173847/0001193125-23-173847-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1055726/000119312523173847/d455953d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-173847
- JSON: https://secwatch.observer/filing/0001193125-23-173847.json
- Plain text: https://secwatch.observer/filing/0001193125-23-173847.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.